Cytokinetics (CYTK) EVP sells 1,930 shares, retaining over 78,000

Rhea-AI Filing Summary

Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 1,930 shares of Common Stock in an open-market transaction at $62.07 per share. The sale was reported as a direct ownership transaction. After this trade, Callos continues to hold 78,185 shares of Cytokinetics common stock.

Insider Trade Summary 10b5-1

Net Seller: 1,930 shares ($119,795)

Net Sell 1 txn

Insider Callos Andrew

Role EVP, Chief Commercial Officer

Sold 1,930 shs ($120K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,930	$62.07	$120K

Holdings After Transaction: Common Stock — 78,185 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		S		1,930	D	$62.07	78,185	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cytokinetics (CYTK) report for Andrew Callos?

Cytokinetics reported that EVP and Chief Commercial Officer Andrew Callos sold 1,930 shares of Common Stock. The transaction was an open-market sale and was disclosed on a Form 4 insider trading report.

At what price did Andrew Callos sell Cytokinetics (CYTK) shares?

Andrew Callos sold 1,930 Cytokinetics Common Stock shares at an average price of $62.07 per share. This reflects an open-market sale as reported in the Form 4 filing.

How many Cytokinetics (CYTK) shares does Andrew Callos hold after the sale?

Following the reported open-market sale, Andrew Callos directly holds 78,185 shares of Cytokinetics Common Stock. This post-transaction balance is disclosed in the Form 4 and shows his remaining direct equity position.

What role does Andrew Callos hold at Cytokinetics (CYTK)?

Andrew Callos serves as Executive Vice President and Chief Commercial Officer at Cytokinetics. His role and officer status are disclosed in the Form 4 insider trading report detailing his recent share sale.

Was the Cytokinetics (CYTK) insider trade an open-market sale?

Yes. The Form 4 classifies Andrew Callos’s transaction as an open-market sale of Common Stock, using transaction code “S,” which indicates a sale in the open market or a private transaction.